Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...

The antiviral Paxlovid has changed the battle against COVID-19. It's so effective that more than 85% of people at risk for severe disease can avoid a bad outcome with a five-day course of the ...

A recent study published in JAMA Network Open examined the efficacy of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized patients with coronavirus disease 2019 (COVID-19) and type 2 diabetes ...

A new Nashville-led study shows that only half of children hospitalized for the flu receive recommended antiviral medications. Dr. James Antoon, assistant professor of Pediatrics at Monroe Carell Jr.